DCDaniela Cologno

Daniela Cologno

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniela Cologno has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Basilar-type migraine patients responsive to lamotrigine: a 5-year follow-up

    by D. Cologno, F. D’oNofrio, O. Castriota, V. Petretta, G. Casucci, A. Russo, G. Bussone

    Five years ago we reported the case of three patients affected by basilar-type migraine (BM) responsive to lamotrigine. At that time, proven treatment options for BM are rather limited and lamotrigine has been tested in BM patients because it was a widely tested treatment for migraine with aura. That positive 1-year experience leaded us to suggest that lamotrigine could be a preventive therapeutic option for BM patients, with and without menstruation association. We now report the five-year follow-up of the same patients to confirm and underlie the possible role of lamotrigine to induce BM attacks remission.


  • Triptans: over the migraine

    by D. Cologno, A. Mazzeo, B. Lecce, C. Mundi, V. Petretta, G. Casucci, F. D’onofrio

    Migraine is a chronic, recurrent, disabling condition that affects millions of people worldwide. Proper acute care treatment for migraineurs is based on triptans, a class of specific medications approved over 20 years ago. Triptans are serotonin (5-HT1B/1D) receptor agonists that are generally effective, well tolerated and safe. Seven triptans are available worldwide, although not all are available in every country, with multiple routes of administration, giving to doctors and patients a wide choice. Despite the similarities of the available triptans, pharmacological heterogeneity offers slightly different efficacy profiles. Triptans are not pain medications, they are abortive migraine medications which cannot prevent migraines. In addition to migraine attacks, triptans are also helpful for cluster headaches. If they are useful in other primary headaches rather than migraine and cluster headache it is yet to be addressed. In the literature there are only limited controlled clinical data to support a migraine-selective activity for triptans. Reports are available about efficacy of triptans to stop attacks of other types of primary headache, such as tension type headache, hypnic headache and other rare forms of primary headaches. On the other hand, sumatriptan failed to treat the indomethacin-responsive primary headache disorders like chronic paroxysmal hemicrania and hemicrania continua, nor was it effective in the myofascial temporal muscle pain or in atypical facial pain. Why triptans are effective in so different types of primary headaches remain unclear. Up to date, it is not clear whether the antimigrainous activity of the triptans involves an action only in the periphery or in the CNS as well. Probably we should consider triptans as “pain killers” and not only as “migraine killers”. We clearly need additional studies on triptans as putative analgesics in well-accepted animal and clinical models of acute and chronic somatic pain.


  • Migraine and movement disorders

    by F. D’oNofrio, P. Barbanti, V. Petretta, G. Casucci, A. Mazzeo, B. Lecce, C. Mundi, D. Cologno

    A large series of clinical and experimental observations on the interactions between migraine and the extrapyramidal system are available. Some previous studies reported high frequency of migraine in some basal ganglia (BG) disorders, such as essential tremor (ET), Tourette’s syndrome (TS), Sydenham’s chorea and more recently restless legs syndrome (RLS). For example, the frequency of migraine headache in a clinic sample of TS patients was found nearly fourfold more than that reported in the general population. To the best of our knowledge, no controlled studies have been conducted to determine a real association. ET and migraine headache have been considered comorbid diseases on the basis of uncontrolled studies for many years. In a recent Italian study, this comorbid association has been excluded, reporting no significant differences in the frequency of lifetime and current migraine between patients with ET and controls. Among mostly common movement disorders, RLS has been recently considered as possibly comorbid with migraine. Studies in selected patient groups strongly suggest that RLS is more common in migraine patients than in control populations, although no population-based study of the coincidence of migraine and RLS has yet been identified. The exact mechanisms and contributing factors for a positive association between migraine and RLS remain unclear. A number of possible explanations have been offered for the association of RLS and primary headache, but the three most attractive ones are a hypothetical dopaminergic dysfunction and dysfunctional brain iron metabolism, a possible genetic linkage and a sleep disturbance. More recently, the role of BG in pain processing has been confirmed by functional imaging data in the caudate, putamen and pallidum in migraine patients. A critical appraisal of all these clinical and experimental data suggests that the extrapyramidal system is somehow related to migraine. Although the primary involvement of extrapyramidal system in the pathophysiology of migraine cannot as yet be proven, a more general role in the processing of nociceptive information and/or maybe part of the complex behavioral adaptive response that characterizes migraine may be suggested.


  • Restless legs syndrome is not associated with migraine with aura: a clinical study

    by F. D’oNofrio, D. Cologno, V. Petretta, C. Finocchi, M. Autunno, G. Marsala, S. Usai, L. Grazzi, S. Omboni, L. Fofi, et al.

    Based on recent data about the association between restless legs syndrome (RLS) and migraine, we performed an observational study on the occurrence of RLS in patients affected by “pure” migraine with aura (pMA). We recruited 63 patients (33 females and 30 males) affected by MA without other types of primary headache among all patients referred in five Italian headache centers in a 1-year period. The prevalence of RLS in pMA patients (9.5%) is similar to that observed in Italian headache-free subjects (8.3%). No significant differences were found between pMA patients with and without RLS about clinical features of MA attacks and systemic and psychiatric diseases were investigated. Moreover, no association appeared between RLS and familial cases of MA. Differently from migraine without aura, our data do not confirm the existence of an association between RLS and MA, not even when a genetic factor is involved.


  • High prevalence of Dopaminergic Premonitory Symptoms in migraine patients with Restless Legs Syndrome: a pathogenetic link?

    by Daniela Cologno, Giulio Cicarelli, Vittorio Petretta, Florindo D’oNofrio, Gennaro Bussone

    In order to assess the prevalence of Dopaminergic Premonitory Symptoms (DPS) in migraine patients with Restless Legs Syndrome (RLS), we chose migraine patients from a large Italian clinical headache population previously investigated for an association between primary headaches and RLS. We evaluated a total sample of 164 patients with migraine, in particular 114 with migraine without aura (MO), 10 with migraine with aura (MA) and 40 with MO and MA in various combinations between them or with episodic tension-type headache (ETTH), defined as a “mixed group”. About 20% of all migraine patients referred at least one of the following DPS: yawning, nausea, somnolence or food craving, confirming data already indicated in the literature. Among migraine patients with RLS (25.6%), DPS were referred from about half of the patients (47.6%) compared to those without RLS (47.6% vs. 13.1%; ppp<0.01). No statistical differences were found between clinical and demographic data of the subgroups or related to medical conditions investigated (anxiety, depression, sleep disorders, body mass index). It is interesting that the chances of having RLS in migraine patients were more than 5 times higher in the presence of DPS. These results could support a hypothetical dopaminergic imbalance in RLS and migraine, as the dopamine is involved in the pathogenesis of both disorders and it is responsible for the migraine DPS reported above.


  • ATP1A2 gene mutations are not present in two sisters with basilar-type migraine associated with menses

    by Daniela Cologno, Florindo D’oNofrio, Teresa Esposito, Fernando Gianfrancesco, Vittorio Petretta, Gerardo Casucci, Fabio Frediani, Maria Gabriella Buzzi, Gennaro Bussone

    Basilar-type migraine (BM) and hemiplegic migraine are clinically distinct subtypes of migraine with aura, however they do share clinical features and it is possible they may share genetic bases. In recent years, ATP1A2 and other gene mutations have been discovered in familial and sporadic hemiplegic migraine. More recently, an ATP1A2 mutation has been identified in an Italian family with BM. In this study we document the absence of ATP1A2 mutations in two Italian sisters with menstrual BM, suggesting that other genes are involved in the condition. L’emicrania di tipo basilare e l’emicrania emiplegica rappresentano due entità cliniche distinte, entrambi sottotipi di emicrania con aura, sebbene condividano alcuni aspetti cliniche e verosimilmente un comune substrato genetico. È recente la scoperta in una famiglia italiana di pazienti affetti da emicrania di tipo basilare di una mutazione nel gene ATP1A2, la stessa mutazione già individuata in alcuni pazienti affetti da emicrania emiplegica familiare e sporadica. Viene riportato il caso di due sorelle italiane affette da emicrania di tipo basilare frequentemente associata al ciclo mestruale in cui non è stata individuata la mutazione nel gene ATP1A2. Tale osservazione permette di ipotizzare che nell’emicrania di tipo basilare “mestruale” siano coinvolti geni differenti.

  • Basilar-type migraine responsive to lamotrigine: three case reports

    by F. D'ONofrio, D. Cologno, V. Petretta, G. Casucci, G. Bussone

    Basilar-type migraine (BM) has been recognised in the revised International Classification of Headache Disorders as a distinct clinical entity (subtype of migraine with aura), characterised by disturbing migraine aura clearly originating from the brainstem or from both hemispheres simultaneously affected. It differs from familial and sporadic hemiplegic migraines by the absence of motor deficit. Lamotrigine has been shown to be effective in preventing migraine aura symptoms in typical aura and in some cases of BM. We tried lamotrigine in three female cases of BM.


  • Adult abdominal migraine: a new syndrome or sporadic feature of migraine headache? A case report

    by F. D'ONofrio, D. Cologno, M. G. Buzzi, V. Petretta, C. Caltagirone, G. Casucci, G. Bussone

    Abdominal migraine is one of the variants of migraine headache typically occurring in children and coded as 1.3.2 in the revised edition of IHS classification within the group ‘Childhood periodic syndromes that are commonly precursors of migraine’. The affected children frequently develop typical migraine later in their life. We report a case of a 23 years old woman affected by attacks of recurrent abdominal pain accompanied by migraine. Abdominal pain attacks started in the adolescence and persisted without headache until the patient was 21. At this time, she experienced migraine pain accompanied by nausea, photophobia and phonophobia and associated to acute abdominal pain. Neuroimaging investigations and laboratory testing excluded any underlying organic disease. Complete remission of abdominal attacks was obtained during 4‐month treatment period with pizotifen. Attacks fulfil IHS diagnostic criteria for ‘abdominal migraine’, although of late onset. This case report suggests that ‘abdominal migraine’ is a migraineous disorder to be hypothesized in adult patients after having disclosed any organic disease. As reported in the literature, ‘adult abdominal migraine’ is a sporadic migraine subtype in adult patients and it is not to be considered as a new migraineous syndrome.


  • Open Access

    Psychiatric disorders and pain location in unilateral migraineurs

    by D. Cologno, M. G. Buzzi, G. A. Carlesimo, P. Cicinelli, A. Costa, L. Fadda, R. Formisano, B. Marconi, S. Pero, C. Caltagirone

    To explore the relationship between the side of pain during attacks and psychopathological features in strictly unilateral migraine, we recruited 35 patients affected by migraine with and/or without aura diagnosed according to the revised ICHD–II criteria. Seventeen patients had right side–locked pain (R–SUM), 11 had left side–locked (L–SUM) and 7 had side–shifting pain (SSM). Patients were administered the Hamilton Anxiety Scale, the State and Trait Anxiety Inventory–State Anxiety, the Beck Depression Inventory and the 20–item Toronto Alexithymia Scale. Statistical analyses showed that the L–SUM group was significantly more anxious and depressed than the other two groups of patients. Our preliminary data suggest that strictly left unilateral migraine is associated with more severe anxiety and depression. This finding appears to be consistent with studies that reported a higher degree of these disorders in patients with left cerebral hemispheric damage.


  • An Epidemiological Study of Migraine with Aura in the San Severo General Population: A Pilot Research Project of Cooperation between Neurologists and General Practitioners

    by Daniela Cologno, Gian Camillo Manzoni, D Drion Medical Association

    Objectives: (A) To define the lifetime prevalence of migraine with aura (MA) in patients recruited in general practices for an epidemiologic study by the University of Parma Headache Centre from the general population of San Severo, Italy, and (B) to assess the recognition of MA in general practice. Methods: The study was conducted over a period of 5 consecutive months (January to May 2001) on patients aged 18–65, taken from the following general practice populations: (a) from the patient population of 4 general practitioners (GPs; 3,616 patients) and (b) from the patient population of 12 GPs (12,996 patients). The clinical diagnosis of MA was subsequently confirmed by a headache specialist. Results: For objective A, 648 patients (420 women and 228 men) were interviewed; MA diagnosis was confirmed in 10 patients (7 women and 3 men), lifetime MA prevalence being 1.5%. For objective B, 150 ‘suspected’ MA cases (96 women and 54 men) were reported by the 12 GPs; however, the diagnosis of MA was confirmed in only 3 cases (2 women and 1 man). Conclusion: The prevalence of MA observed in our small sample of the general practice patient population was comparable with that observed in the general population of San Severo, Italy. The results also suggest that GPs may be overestimating the number of cases of MA in their patient population.